ArticleJournal of immunology (Baltimore, Md. : 1950)2018
Characterization of the Antigenic Heterogeneity of Lipoarabinomannan, the Major Surface Glycolipid of
Open access · hybridAbstract read
In one paragraph
Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 71 citations in OpenAlex.
- Diagnostic accuracy of 3 urine lipoarabinomannan tuberculosis assays in HIV-negative outpatients.The Journal of clinical investigation · 2020Trial
- Trial
- Trial
- Using Synthetic Glycans to Investigate Anti-Glycan Antibodies and Explore Their Medical Potential.Angewandte Chemie (International ed. in English) · 2026Review
- Novel human monoclonal antibodies with enhanced sensitivity for lipoarabinomannan antigens present in urines of TB patients.bioRxiv : the preprint server for biology · 2026Article
- Antigen heterogeneity in the development and clinical validation of a multiplexed urine test for tuberculosis.Communications medicine · 2026Article
- Cryo-EM and cryo-ET reveal the molecular architecture and host interactions of mycobacteriophage Douge.Cell reports · 2025Article
- Article
- A novel method for detecting Lipoarabinomannan in urine with the promise of meeting the WHO target product profile for the diagnosis of tuberculosis.Tuberculosis (Edinburgh, Scotland) · 2025Article
- Real-world diagnostic accuracy of lipoarabinomannan in three non-sputum biospecimens for pulmonary tuberculosis disease.EBioMedicine · 2024Article
- Novel automated AIMLAM for diagnosis ofFuture microbiology · 2024Article
- Impact of Methylthioxylose Substituents on the Biological Activities of Lipomannan and Lipoarabinomannan inACS infectious diseases · 2024Article
- Selective Glycan Labeling of Mannose-Containing Glycolipids in Mycobacteria.Journal of the American Chemical Society · 2024Article
- Urine lipoarabinomannan concentrations among HIV-negative adults with pulmonary or extrapulmonary tuberculosis disease in Vietnam.PLOS global public health · 2024Article
- Impact of Mycobacterium tuberculosis Glycolipids on the CD4+ T Cell-Macrophage Immunological Synapse.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Collected Thoughts on Mycobacterial Lipoarabinomannan, a Cell Envelope Lipoglycan.Pathogens (Basel, Switzerland) · 2023Review
- Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan.JCI insight · 2023Article
- Monoclonal antibodies to lipoarabinomannan/arabinomannan - characteristics and implications for tuberculosis research and diagnostics.Trends in microbiology · 2023Review
- Isolation and purification of lipoarabinomannan from urine of adults with active TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- Proteinase K-pretreated ConA-based ELISA assay: a novel urine LAM detection strategy for TB diagnosis.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 5 countries.
Alok ChoudharyPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103.
Deendayal PatelPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103.ORCID 0000-0003-4483-638X
William HonnenPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103.
Zhong LaiPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103.
Raja Sekhar PrattipatiPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103.ORCID 0000-0002-6464-6834
Ruixiang Blake ZhengAlberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada.ORCID 0000-0001-8200-6534
Ying-Chao HsuehPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103.ORCID 0000-0003-2600-5718
Maria Laura GennaroPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103.
Alfred LardizabalGlobal Tuberculosis Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103.ORCID 0000-0003-3273-1097
Blanca I RestrepoUniversity of Texas Health Science Center at Houston, School of Public Health at Brownsville, Brownsville, TX 78520.ORCID 0000-0002-3743-9098
Moncerrato Garcia-ViverosSecretaria de Salud de Tamaulipas, Ciudad Victoria 87000, Mexico.
Maju JoeAlberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada.ORCID 0000-0003-0664-5275
Yu BaiAlberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada.ORCID 0000-0002-7481-7035
Ke ShenAlberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada.ORCID 0000-0003-0700-7769
Kamar SahloulAlberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada.
John S SpencerMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523; and.
Delphi ChatterjeeMycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523; and.
Tobias BrogerFoundation for Innovative New Diagnostics, Geneva 1202, Switzerland.ORCID 0000-0002-7959-1055
Todd L LowaryAlberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada.ORCID 0000-0002-8331-8211
Abraham PinterPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103; pinterab@njms.rutgers.edu.ORCID 0000-0002-3262-3304
Rutgers, The State University of New Jersey · USUniversity of Alberta · CAColorado State University · USFIND · CHSecretaria de Salud · MX
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipoarabinomannan (LAM), the major antigenic glycolipid of
Indexed as
AnimalsAntibody SpecificityEpitope MappingHumansLipopolysaccharidesMiceMycobacterium tuberculosislipoarabinomannanLipopolysaccharides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.